Floatz logo

19 assets in Fallopian Tube Clear Cell Adenocarcinoma

Therapeutic assets addressing Fallopian Tube Clear Cell Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carboplatin
Fallopian Tube Clear Cell Adenocarcinoma
NRG OncologyP3BB (70)
Olaparib
Fallopian Tube Clear Cell Adenocarcinoma
National Cancer Institute (NCI)P3BB (67)
Adriamycin
Fallopian Tube Clear Cell Adenocarcinoma
National Cancer Institute (NCI)P3BB (66)
Cediranib
Fallopian Tube Clear Cell Adenocarcinoma
National Cancer Institute (NCI)P3BB (64)
Cyclophosphamide
Fallopian Tube Clear Cell Adenocarcinoma
Mayo ClinicP2B (63)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Fallopian Tube Clear Cell Adenocarcinoma
Mayo ClinicP2B (62)
Nogitecan
Fallopian Tube Clear Cell Adenocarcinoma
National Cancer Institute (NCI)P2/3B (60)
Pembrolizumab
Fallopian Tube Clear Cell Adenocarcinoma
Mayo ClinicP2B (60)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Fallopian Tube Clear Cell Adenocarcinoma
Mayo ClinicP2B (58)
Atezolizumab
Fallopian Tube Clear Cell Adenocarcinoma
National Cancer Institute (NCI)P2/3B (57)
Docetaxel
Fallopian Tube Clear Cell Adenocarcinoma
National Cancer Institute (NCI)P3B (57)
Adsorbed Purified Pertussis Vaccine
Fallopian Tube Clear Cell Adenocarcinoma
Mayo ClinicP2CCC (53)
Diphtheria Toxoid
Fallopian Tube Clear Cell Adenocarcinoma
Mayo ClinicP2CCC (53)
Diphtheria Toxoid Adsorbed
Fallopian Tube Clear Cell Adenocarcinoma
Mayo ClinicP2CCC (53)
Durvalumab
Fallopian Tube Clear Cell Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Lorigerlimab
Fallopian Tube Clear Cell Adenocarcinoma
MacroGenicsP2CCC (53)
Pegcetacoplan
Fallopian Tube Clear Cell Adenocarcinoma
Roswell Park Cancer InstituteP2CCC (53)
Tetanus Toxoid
Fallopian Tube Clear Cell Adenocarcinoma
Mayo ClinicP2CCC (53)
Tolinapant
Fallopian Tube Clear Cell Adenocarcinoma
National Cancer Institute (NCI)P1/2CC (47)